title: Policies, Guidelines and Consensus Statements: Pharmacologic Management of Type 2 Diabetes-2015 Interim Update.
authors.forename: William
authors.initials: W
authors.lastname: Harper
authors.forename: Maureen
authors.initials: M
authors.lastname: Clement
authors.forename: Ronald
authors.initials: R
authors.lastname: Goldenberg
authors.forename: Amir
authors.initials: A
authors.lastname: Hanna
authors.forename: Andrea
authors.initials: A
authors.lastname: Main
authors.forename: Ravi
authors.initials: R
authors.lastname: Retnakaran
authors.forename: Diana
authors.initials: D
authors.lastname: Sherifali
authors.forename: Vincent
authors.initials: V
authors.lastname: Woo
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Yale
authors.forename: Alice Y Y
authors.initials: AY
authors.lastname: Cheng
mesh_terms: D002170:Canada / Q000453:epidemiology; D000068896:Canagliflozin / Q000494:pharmacology / Q000627:therapeutic use; D032921:Consensus; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D019468:Disease Management; D006291:Health Policy; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic / Q000592:standards*; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors
chemical_list: D007004:Hypoglycemic Agents; C089180:SLC5A2 protein, human; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D000068896:Canagliflozin